Evidence map›Paper›PMID 30192925›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2019

Safety, Tolerability, and Efficacy of Generic Dolutegravir-containing Antiretroviral Therapy Regimens Among South Indian Human Immunodeficiency Virus-infected Patients.

Nagalingeswaran Kumarasamy, Sandeep Prabhu, Ezhilarasi Chandrasekaran, Selvamuthu Poongulali, Amrose Pradeep, Devaraj Chitra, Ramasamy Balakrishnan, Constance A Benson

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Nagalingeswaran KumarasamyYRGCARE Medical Centre, Voluntary Health Services Chennai, India.
Sandeep PrabhuSchool of Medicine, University of California, San Diego.
Ezhilarasi ChandrasekaranYRGCARE Medical Centre, Voluntary Health Services Chennai, India.
Selvamuthu PoongulaliYRGCARE Medical Centre, Voluntary Health Services Chennai, India.
Amrose PradeepYRGCARE Medical Centre, Voluntary Health Services Chennai, India.
Devaraj ChitraYRGCARE Medical Centre, Voluntary Health Services Chennai, India.
Ramasamy BalakrishnanYRGCARE Medical Centre, Voluntary Health Services Chennai, India.
Constance A BensonDepartment of Infectious Diseases, University of California, San Diego.

Funding

UCSD Department of Medicine HIV/AIDS Clinical Trials UnitUM1AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TIMOTHY J. WILKIN · 2012 to 2026
$50.4M
NIAID NIH HHS UM1 AI069432
6 · The paper itself

Abstract

In this first study of generic dolutegravir (DTG)-containing regimens in a low-resource setting, we assessed safety, tolerability, and efficacy within a prospective cohort of 564 patients with at least 6 months of clinical follow-up. We provide support for a large-scale transition to DTG as part of first-line regimens.

Indexed as

HIV-1AdultAntiretroviral Therapy, Highly ActiveDolutegravirFemaleHeterocyclic Compounds, 3-RingHIV InfectionsHIV Integrase InhibitorsHumansIndiaMaleMiddle AgedOxazinesPiperazinesPyridonesTreatment OutcomeDolutegravirHeterocyclic Compounds, 3-RingHIV Integrase InhibitorsOxazinesPiperazinesPyridonesdolutegravirefficacyHIVresource-limited settingsafety

Identifiers

PMID30192925
PMCPMC7182123

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.